A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer (NCT02747004)
A Randomized, Open-Label, Phase 2 Study of Abemaciclib Plus Tamoxifen or Abemaciclib Alone, in Women With Previously Treated Hormone Receptor-Positive, HER2-Negative, Metastatic Breast Cancer
🩺 Plain-English Summary (8th-Grade Level)
The main purpose of this study is to evaluate the safety and efficacy of abemaciclib plus tamoxifen or abemaciclib alone in women with previously treated hormone receptor-positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), metastatic breast cancer.
Who can join: Review the eligibility criteria below.
Location: The University of Arizona Cancer Center — Tucson, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (59 Sites)
Showing the first 25 of 59 sites.
- The University of Arizona Cancer Center — Tucson, Arizona
- Dartmouth Hitchcock Medical Center — Lebanon, New Hampshire
- Tennessee Oncology PLLC — Nashville, Tennessee
- The Center for Cancer and Blood Disorders — Fort Worth, Texas
- University of Wisconsin Clinical Research Center — Madison, Wisconsin
- CENIT Centro de Neurociencias, Investigación y Tratamiento — CABA, Buenos Aires
- Fundacion Ars Medica — San Salvador de Jujuy, Jujuy Province
- Clinica Viedma — Viedma, Río Negro Province
- Instituto de Oncología de Rosario — Rosario, Santa Fe Province
- Centro Para la Atención Integral del Paciente Oncologico (CAIPO) — San Miguel de Tucumán, Tucumán Province
- Sanatorio Parque — Salta,
- Medizinische Universitaet Graz — Graz, Styria
- Universitätsklinik Innsbruck — Innsbruck, Tyrol
- AKH — Vienna,
- Universitair Ziekenhuis Gent — Ghent, Oost-Vlaanderen
- VITAZ — Sint-Niklaas, Oost-Vlaanderen
- Grand Hopital de Charleroi-Site Notre-Dame — Charleroi,
- Centre Hospitalier Universitaire Sart Tilman — Liège,
- Hospital São Lucas - PUCRS - ONCOLOGY — Porto Alegre, Rio Grande do Sul
- Fundação Pio XII - Hospital de Câncer de Barretos — Barretos, São Paulo
- Icesp - Instituto Do Câncer Do Estado de São Paulo — São Paulo,
- Clinica de Pesquisas e Centro de Estudos em Oncologia Ginecológica e Mamária LTDA — São Paulo,
- Masarykuv onkologicky ustav — Brno, Czech Republic
- Fakultni nemocnice Kralovske Vinohrady — Prague,
- Fakultni Poliklinika VFN — Prague,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Metastatic Breast Cancer
- Assessing the Time Demands of Cancer — Birmingham, Alabama
- Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer — Birmingham, Alabama
- A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer — Commack, New York
- Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor — Washington D.C., District of Columbia
- Roll-over Study to Allow Continued Access to Ribociclib — Chandler, Arizona
Explore by condition: All Metastatic Breast Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.